Position in ALKS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,504,354
+$2,709,415 QoQ
Shares Held
66,877
+135.4% QoQ
Ownership
0.040%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#139
of 421 holders
Holding Since
Mar 2022
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Aquatic Capital Management LLC holds $56,202,914 across 24 Drug Manufacturers - Specialty & Generic names. ALKS ranks #5 (6.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
300,272 | $21,577,545 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
10,212 | $5,533,167 | |
| 3 | INDV |
Indivior Pharmaceuticals, Inc.
|
122,213 | $5,014,399 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
362,895 | $3,628,950 | |
| 5 | ALKS |
Alkermes plc.
This page
|
66,877 | $3,504,354 | |
| 6 | LQDA |
Liquidia Corp
|
39,623 | $3,159,141 | |
| 7 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
41,528 | $2,655,715 | |
| 8 | NBIX |
Neurocrine Biosciences Inc
|
10,684 | $1,800,681 |
All Filings in ALKS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,504,354 | 66,877 | Shares | Sole | 2026-08-14 | |
| 2025-12-31 | $794,939 | 28,411 | Shares | Sole | 2026-02-17 | |
| 2024-06-30 | $200,030 | 8,300 | Shares | Sole | 2024-08-14 | |
| 2023-09-30 | $714,255 | 25,500 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $1,054,810 | 33,700 | Shares | Sole | 2023-08-14 | |
| 2022-12-31 | $804,804 | 30,800 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $716,793 | 32,100 | Shares | Sole | 2022-11-14 | |
| 2022-03-31 | $73,668 | 2,800 | Shares | Sole | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||